Clinical Trials Logo

Filter by:
NCT ID: NCT01493583 Completed - Obesity Clinical Trials

Central Nervous Processing of Visual Food Stimuli in Severely Obese Subjects

Start date: September 2009
Phase: N/A
Study type: Observational

Recent evidence has pointed to distinct alterations of brain functions in obese subjects some of which may even be causative for their obesity. The objective of this study was to examine food and non food related alterations in brain functions after excessive weight loss due to Roux-en Y gastric bypass surgery (RYGB), one of the most successful therapeutic approaches for long lasting weight loss. The investigators hypothesized that obese as compared with lean women show an altered activation pattern in the brain areas involved in the homeostatic regulation of eating behavior, i.e. the hypothalamus, in reward-related brain areas, such as the orbital frontal cortex (OFC) and the striatum as well as in prefrontal inhibitory control areas. Furthermore, the investigators hypothesized that women who had undergone a RYGB operation show a brain activity pattern that more closely mimics that of lean than severely obese women. In a supplementary test the investigators will assess gastrointestinal and metabolic response to a standardized meal in order to elucidate putative correlation of these responses with the results of fMRI scannings.

NCT ID: NCT01493531 Completed - Gout Clinical Trials

Combining Lesinurad With Allopurinol in Inadequate Responders

CLEAR 2
Start date: December 2011
Phase: Phase 3
Study type: Interventional

This study will compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to allopurinol.

NCT ID: NCT01492790 Completed - Cholecystitis Clinical Trials

Cholecystectomy First vs Sequential Common Bile Duct Imaging + Cholecystectomy

CCK first
Start date: June 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate if cholecystectomy first (studied group) versus sequential common bile duct imaging/cholecystectomy (control group) result in a decrease of hospital stay, morbidity/mortality and costs in the management of patients with a suspicion of gallstone migration.

NCT ID: NCT01492777 Completed - Clinical trials for Thromboembolic Diseases

Pharmacogenetics of Acenocoumarol

Start date: November 2008
Phase: N/A
Study type: Observational

The use of oral anticoagulation is marked by an elevated risk of adverse drug events (ADE) due to a narrow therapeutic window leading to important medical and economical consequences. The risk of ADE is increased partly by drug interactions and recently identified genetic factors influencing the metabolism of coumarins (polymorphism of the cytochrome P450 CYP2C9) as well as the target enzyme of the coumarins (polymorphism of the vitamin K epoxide reductase complex subunit 1 (VKORC1). The objective is to determine the impact of several genotypes on acenocoumarol treatment and on vulnerability to drug-drug interactions.

NCT ID: NCT01492426 Completed - Hepatitis C Clinical Trials

Study Comparing BMS-790052 (Daclatasvir) to Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Untreated Hepatitis C Patients

COMMAND-3
Start date: January 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effectiveness of BMS-790052 (Daclatasvir) and Telaprevir when given in combination with Peginterferon alfa-2a and Ribavirin in genotype 1b patients

NCT ID: NCT01491932 Completed - Parkinson Disease Clinical Trials

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Start date: March 2012
Phase: Phase 2
Study type: Interventional

This study is to evaluate long-term safety, tolerability and efficacy for AFQ056 in patients who have completed an AFQ056A study in Parkinson's disease L-dopa induced dyskinesias (PD-LID).

NCT ID: NCT01491529 Completed - Parkinson Disease Clinical Trials

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Start date: April 2012
Phase: Phase 2
Study type: Interventional

This study will assess the efficacy and safety of modified release AFQ056 in patients that have Parkinson's Disease L-dopa Induced Dyskinesias (PD-LID)

NCT ID: NCT01490814 Completed - Clinical trials for Symptomatic Paroxysmal Atrial Fibrillation (PAF)

FIRE AND ICE: Comparative Study of Two Ablation Procedures in Patients With Atrial Fibrillation

Start date: December 2011
Phase: N/A
Study type: Interventional

Comparing efficacy and safety of isolation of the pulmonary veins (PV) using a Cryoballoon catheter versus a radiofrequency ablation with a ThermoCool catheter in patients with paroxysmal atrial fibrillation.

NCT ID: NCT01490294 Completed - Clinical trials for Magnetic Resonance Imaging

Myocardial Perfusion MRI

Start date: March 2004
Phase: Phase 2
Study type: Interventional

The object of this study is to compare four different dosages of Gadavist 1.0 in cardiac Magnetic Resonance Tomography (MRT) imaging with the imaging results of a cardiac SPECT examination in terms of diagnostic quality. For this purpose Gadavist dosages of 0.01 mmol/kg, 0.025 mmol/kg, 0.05 mmol/kg or 0.1mmol/kg body weight are administered. A study participant receives the respective dose twice i.e. at rest and at stress using Adenosine (which puts circulation into a state of stress similar to that of physical exercise). The time between both injections is 10-15 min. The total imaging time is about 45 min.

NCT ID: NCT01489670 Completed - Ocular Hypertension Clinical Trials

Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Start date: September 2011
Phase: N/A
Study type: Observational

This study will assess the efficacy, safety, tolerability and persistence of use of Lumigan ® 0.01% in patients diagnosed with primary open-angle glaucoma or ocular hypertension who are treated per routine clinical practice.